- Home
- PET vs ANTX Comparison
PET vs ANTX Comparison
Compare PET & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PET
- ANTX
- Stock Information
- Founded
- PET 2015
- ANTX 2017
- Country
- PET United States
- ANTX United States
- Employees
- PET N/A
- ANTX N/A
- Industry
- PET EDP Services
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- PET Technology
- ANTX Health Care
- Exchange
- PET Nasdaq
- ANTX Nasdaq
- Market Cap
- PET 41.5M
- ANTX 63.5M
- IPO Year
- PET N/A
- ANTX 2022
- Fundamental
- Price
- PET $0.85
- ANTX $1.03
- Analyst Decision
- PET Strong Buy
- ANTX Buy
- Analyst Count
- PET 5
- ANTX 4
- Target Price
- PET $4.40
- ANTX $2.50
- AVG Volume (30 Days)
- PET 119.5K
- ANTX 157.4K
- Earning Date
- PET 11-06-2024
- ANTX 11-07-2024
- Dividend Yield
- PET N/A
- ANTX N/A
- EPS Growth
- PET N/A
- ANTX N/A
- EPS
- PET N/A
- ANTX N/A
- Revenue
- PET $85,343,000.00
- ANTX N/A
- Revenue This Year
- PET $9.11
- ANTX N/A
- Revenue Next Year
- PET $14.58
- ANTX N/A
- P/E Ratio
- PET N/A
- ANTX N/A
- Revenue Growth
- PET 17.14
- ANTX N/A
- 52 Week Low
- PET $0.66
- ANTX $0.87
- 52 Week High
- PET $2.47
- ANTX $22.22
- Technical
- Relative Strength Index (RSI)
- PET 48.82
- ANTX 37.87
- Support Level
- PET $0.77
- ANTX $1.03
- Resistance Level
- PET $0.86
- ANTX $1.08
- Average True Range (ATR)
- PET 0.05
- ANTX 0.03
- MACD
- PET -0.00
- ANTX 0.01
- Stochastic Oscillator
- PET 47.65
- ANTX 0.00
About PET Wag! Group Co.
Wag Group Co develops and supports a proprietary marketplace technology platform available as a website and mobile app that enables independent Pet Caregivers to connect with pet parents. The platform allows pet parents to make pet service requests in the platform, which can then be fulfilled by Pet Caregivers. Wag supports dog walking, pet sitting, pet boarding, drop-in visits at the pet parent's home, advice from licensed pet experts, training services, pet insurance comparison tools, and pet wellness plans.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.